Best Drug Discovery Software - Page 8

Luminata

Bring your analytical, chemical, and process data together in one interface with Luminata. This decision support software enables pharmaceutical development teams to work collaboratively without the hassle of spreadsheets or incompatible file formats. Applications include characterizing composite materials, impurity management, process control, forced degradation, batch genealogy, and externalization.

MAbSilico

Macromoltek

Macromoltek is a pioneering biotech company that leverages advanced computational modeling and artificial intelligence to revolutionize antibody discovery and engineering. By integrating cutting-edge AI-driven technologies, Macromoltek accelerates the development of highly specific and effective antibody therapeutics, reducing time-to-market and enhancing the probability of clinical success. Key Features and Functionality: - AI-Driven Antibody Discovery: Utilizes proprietary algorithms to identify and optimize antibodies with high specificity and affinity, streamlining the discovery process and enabling rapid identification of promising therapeutic candidates. - Computational Structure Modeling: Employs advanced computational tools to predict and refine antibody structures, enhancing accuracy in epitope mapping, developability assessments, and structural optimization, thereby reducing experimental cycles. - Custom Antibody Engineering Partnerships: Offers flexible collaboration models with biotech and pharmaceutical companies, providing tailored antibody design and engineering services that support projects from early research stages to clinical development. Primary Value and Solutions Provided: Macromoltek addresses the challenges of traditional antibody development by offering an AI-driven platform that accelerates the discovery and optimization of therapeutic antibodies. This approach reduces the time and risk associated with drug development pipelines, enabling biotech and pharmaceutical partners to achieve breakthroughs in precision medicine and deliver more effective, targeted treatments.

Manas AI

Manas AI is an innovative platform dedicated to revolutionizing drug discovery, particularly in the field of oncology. By integrating advanced artificial intelligence with computational chemistry and biology, Manas AI aims to expedite the identification and development of effective treatments for aggressive cancers such as triple-negative breast cancer, prostate cancer, and lymphoma. The platform utilizes AI-driven molecular docking techniques to rapidly analyze extensive chemical libraries, significantly accelerating the process of finding promising therapeutic candidates. This approach not only enhances the efficiency of drug discovery but also reduces associated costs, ultimately aiming to bring effective cancer treatments to patients more swiftly.

MD+ Discovery

We enable life scientists to transform Mass Spectrometry (MS) data to knowledge in minutes with seamless data processing, automated quality control, secure sharing and intelligent knowledge integrations so they can accelerate scientific discoveries and develop life-saving preventions and treatments.

Meddenovo Drug Design

Meddenovo Drug Design specializes in accelerating pharmaceutical research and development through advanced computational biochemistry techniques, with a particular focus on cyclic peptides. By integrating artificial intelligence with physical computational methods, Meddenovo offers innovative solutions tailored to the unique challenges of drug discovery. Their technology platform is designed to enhance efficiency and reduce costs, potentially decreasing drug discovery expenses by up to 30%. Founded by academics with over a decade of experience in drug design and biomolecular modeling, Meddenovo aims to bridge the gap between computational chemistry and experimental research, facilitating collaborative drug discovery efforts. Key Features and Functionality: - Mexa Screen: A cloud-based computational chemistry software that simplifies in silico testing of cyclic peptides. It calculates binding affinities and drug-like properties, allowing researchers to test hypotheses before committing laboratory resources. Mexa Screen offers an intuitive interface with automated preparation steps and AI-driven interpretations, delivering expert-level results without requiring specialized expertise. - Mexa Design: An AI-powered platform that generates optimized cyclic peptide drug candidates from scratch, even in the absence of experimental leads. It employs structure-based rational drug design, expanding the chemical space to include non-canonical amino acids, and ensures the synthesizability of candidates. Mexa Design provides researchers with 15 optimized drug-like candidates tailored to their target of interest. Primary Value and Problem Solved: Meddenovo addresses the significant challenge in drug discovery of efficiently designing and testing novel cyclic peptide therapeutics. By leveraging AI and computational chemistry, their platforms reduce the time and cost associated with traditional drug development processes. This approach enables researchers to rapidly identify and optimize potential drug candidates, accelerating the path from concept to clinical trials and ultimately bringing effective therapies to market more swiftly.

Medra AI

Medra AI develops an autonomous scientific experimentation platform that combines robotics with artificial intelligence.

Menten AI

Menten AI is at the forefront of integrating generative artificial intelligence with physics-based modeling and quantum simulations to revolutionize peptide drug design. Their proprietary platform, MAUD 1.0, enables the de novo creation of peptide macrocycles, targeting complex drug targets, including challenging protein-protein interfaces. This innovative approach addresses the limitations of traditional drug discovery methods, facilitating the development of therapeutics with enhanced properties such as nanomolar potency, oral bioavailability, and cell permeability. Key Features and Functionality: - Generative AI Integration: MAUD 1.0 combines generative AI with physics-based models and quantum simulations to design and optimize drug-like peptides, accelerating discovery and expanding the accessible chemical space. - De Novo Peptide Design: The platform designs peptide macrocycles from scratch, enabling the creation of novel therapeutics for complex drug targets. - Multi-Parameter Optimization: MAUD 1.0 optimizes multiple drug-like properties simultaneously, including potency, permeability, and stability, creating a shortcut to the right chemical space and enabling faster, more effective therapeutic discovery. - Validated Performance: The platform has demonstrated nanomolar-level potency, oral bioavailability, cell permeability, and a hit rate exceeding 90% across the preclinical discovery pipeline. Primary Value and User Solutions: Menten AI's MAUD 1.0 platform addresses the challenges of traditional drug discovery by enabling the rapid and efficient design of peptide therapeutics for targets previously considered undruggable. By integrating advanced computational methods, the platform reduces the reliance on large training datasets and accelerates the development of effective drugs with desirable properties. This approach not only streamlines the drug discovery process but also expands the potential for developing treatments for a broader range of diseases, ultimately contributing to the advancement of medicine and patient care.

MetaPharma

Meta-Pharma is an ERP Solution for Pharmaceuticals Industry built on Microsoft Dynamics 365 Business Central. It includes robust accounting and inventory management features and advanced functionality for traceability, lot tracking, regulatory compliance with the DEA, FDA and DSCSA, EDI integration, barcode scanning and warehouse management. These features work together to automate processes and grow your business, increase transparency, and aid in regulatory compliance.

METiS Pharmaceuticals

METiS Pharmaceuticals is the world's first AI-driven drug formulation company.

Molecule GEN

Molecule.one

Naked Biome

Naked Biomedrug discovery platform uses next-generation sequencing to profile healthy and diseased skin to identify unique microbial signatures that naturally aid in the defense against acne.

Nanograb

Neurosnap